ScreenerHero

CRBU Caribou Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · cariboubio.com
0.6174USD-45.60%Mkt Cap: 66.19M $P/E: —

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISP…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap66.19M USD
Enterprise Value36.02M USD
Revenue (TTM)10.04M USD
Gross Profit-73.82M USD
Net Income (TTM)-148.13M USD
Revenue/Share0.10 USD
Last Price0.6174 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees97
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.90
PEG—
EV/EBITDA-0.34
EV/Revenue3.59
P/S12.13
P/B1.23
EPS (TTM)-1.08
EPS (Forward)-1.26
52W Range
0.54602% of range3.535
52W High3.535 USD
52W Low0.5460 USD
Profitability
Gross Margin0.00%
Oper. Margin-1690.39%
EBITDA Margin0.00%
Profit Margin-1327.40%
ROE-121.24%
ROA-84.47%
Growth
Revenue Growth-43.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-110.99M USD
CapEx (TTM)1.36M USD
FCF Margin-593.98%
FCF Yield-90.05%
Net Debt-85.66M USD
Net Debt/EBITDA0.82
Balance Sheet
Debt/Equity0.22
Current Ratio6.49
Quick Ratio6.36
Book Value/Sh0.93 USD
Cash/Share1.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)11.86 USD
Upside (mean)+1820.5%
Target Range4.000 USD – 32.00 USD
4.000+1820.5% to mean32.00
# Analysts7
Ownership
Shares Out.107.21M
Float102.91M
Insiders8.13%
Institutions44.94%
Short Interest
Short Ratio11.1d
Short % Float12.57%
Short % Out.12.11%
Shares Short12.98M
Short (prev mo.)12.47M
Technical
SMA 501.475 (-58.1%)
SMA 2001.737 (-64.5%)
Beta2.31
S&P 52W Chg16.45%
Avg Vol (30d)2.27M
Avg Vol (10d)919.47K
Technical Indicators
RSI (14)11.8
MACD-0.1384
MACD Signal-0.1010
MACD Hist.-0.0374
BB Upper1.598 USD
BB Middle1.251 USD
BB Lower0.9043 USD
BB Width55.45%
ATR (14)0.1024 USD
Vol Ratio (20d)32.18x